Efficacy and safety of selinexor in the treatment of AML: A protocol for systematic review and meta-analysis.
Efficacy and safety of selinexor in the treatment of AML: A protocol for systematic review and meta-analysis.
复制标题
DOI：
10.1097/md.0000000000027884
复制
发表时间：
2021-12-10
期刊：
影响因子：
1.6
通讯作者：
Cui S
中科院分区：
文献类型：
--
作者：
Yu L;Yin X;Si Y;Wang Y;Wang J;Cui S
急性髓性白血病（AML）是成人人群中最常见的白血病，约占所有病例的80%。尽管治疗方案取得了进展，但预后仍然很差，特别是在老年人群中。Selinexor是一种一流的口服小分子Exportin-1抑制剂，正在开发用于治疗各种癌症，包括AML。赛林克斯治疗AML的有效性和安全性问题仍是关注的焦点。因此，我们进行了一项荟萃分析，以评估赛林克斯治疗AML的疗效和安全性。根据检索策略，无论发表日期或语言如何，将从8个数据库中检索赛林克斯治疗AML的随机对照试验。首先根据入选标准对文献进行筛选，并使用科克伦协作网的工具对纳入文献进行质量评价。采用Rev Man 5.3和STATA 14.2软件进行传统Meta分析。最后，对证据质量和建议强度的评价将采用建议、评估、发展和评价的分级方法。本研究将评价赛林克斯治疗AML的有效性和安全性，从而为AML的临床决策提供更多的证据支持。本研究将为AML患者的临床用药提供更多的参考。
Acute myeloid leukemia (AML) is the most common leukemia among the adult population and accounts for about 80% of all cases. Despite advancements in therapeutic regimens, the prognosis remains very poor, especially in the elderly population. Selinexor is a first-in-class, oral, small molecule Exportin-1 inhibitor that is being developed for the treatment of a variety of cancers, including AML. The efficacy and safety issues of selinexor in the treatment of AML are still the focus of attention. Therefore, we conducted a meta-analysis to evaluate the efficacy and safety of selinexor in the treatment of AML. According to the search strategy, regardless of publication date or language, randomized controlled trials of selinexor for AML will be retrieved from 8 databases. First of all, the literature was screened according to the eligibility criteria, and use the Cochrane Collaboration's tool to assess the quality of the included literature. Then, using Rev Man 5.3 and STATA 14.2 software for traditional meta-analysis. Finally, the evaluation of the quality of the evidence and the strength of the recommendations will adopt the Grading of Recommendations, Assessment, Development, and Evaluation method. This study will evaluate the efficacy and safety of selinexor for AML, thereby providing more evidence support for clinical decision-making in AML. Our research will provide more references for the clinical medication of patients with AML.